• 1
    Collins HLK, Kaufmann SHE. The many faces of host responses to tuberculosis. Immunology 2001; 103: 19.
  • 2
    Raviglione MC. The TB epidemic from 1992 to 2002. Tuberculosis 2002; 83: 414.
  • 3
    Godfrey-Faussett P, Ayles H. Can we control tuberculosis in high HIV prevalence settings? Tuberculosis 2003; 83: 6876.
  • 4
    Smith D. Protective efficacy of BCG in experimental tuberculosis. Adv Tuberc Res 1995; 22: 197.
  • 5
    Fine PE. The BCG story. Lessons from the past and implications for the future. Rev Infect Dis Supplement 1989; 2: S3539.
  • 6
    Cole ST, Brosch R, Parkhill J et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 53744.
  • 7
    Gurunathan S, Wu CY, Freidag BL, Seder RADNA vaccines: immunology, application and optimization. Annu Rev Immunol 2000; 18: 92774.
  • 8
    Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 174659.
  • 9
    Tascon RE, Soares CS, Ragno S, Stavropoulos E, Hirst EM, Colston MJ. Mycobacterium tuberculosis-activated dendritic cells induce protective immunity in mice. Immunology 2000; 99: 47380.
  • 10
    Stacey KJ, Sweet MJ, Hume DA. Macrophages ingest and are activated by bacterial DNA. J Immunol 1996; 157: 211622.
  • 11
    Yamamoto S, Yamamoto T, Shimada S et al. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol 1992; 36: 98397.
  • 12
    Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 5469.
  • 13
    Bonato VL, Lima VM, Tascon RE, Lowrie DB, Silva CL. Identification and characterization of protective T cells in hsp65 DNA-vaccinated and Mycobacterium tuberculosis-infected mice. Infect Immun 1998; 66: 16975.
  • 14
    Lowrie DB, Tascon RE, Bonato VL et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999; 400: 26971.
  • 15
    Hingley-Wilson SM, Sly LM, Reiner NE, MacMaster RW. The immunobiology of the mycobacterial infected macrophage. Mod Asp Immunobiol 2000; 1: 96101.
  • 16
    Caruso AM, Serbina N, Klein E, Triebold K, Bloom BR, Flynn JL. Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. J Immunol 1999; 162: 540716.
  • 17
    Flynn JL, Goldstein MM, Triebold KJ, Koller B, Bloom BR. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 1992; 89: 120137.
  • 18
    Ladel CH, Blum C, Dreher A, Reifenberg K, Kopf M, Kaufmann HE. Lethal tuberculosis in interleukin-6-deficient mutant mice. Infect Immun 1997; 65: 48439.
  • 19
    Cooper AM, Magram J, Ferrante J, Orme IM. Interleukin 12 (IL-12) is crucial to development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J Exp Med 1997; 186: 3945.
  • 20
    Flynn JL, Goldstein MM, Chan J et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995; 2: 56172.
  • 21
    Murray PJ, Young RA. Increased antimycobacterial immunity in interleukin-10-deficient mice. Infect Immun 1999; 67: 308795.
  • 22
    Hernandez-Pando R, Orozco H, Arriaga K, Sampieri A, Larriva-Sahd J, Marina-Madrid V. Analysis of the local kinetics and localization of interleukin-1-alpha, tumor necrosis factor-alpha and transforming growth factor-beta, during the course of experimental pulmonary tuberculosis. Immunology 1997; 90: 60717.
  • 23
    Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russel DG, Orme IM. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993; 6: 22437.
  • 24
    Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178: 224954.
  • 25
    Gonzalez-Juarrero M, Orme IM. Characterization of murine lung dendritic cells infected with Mycobacterium tuberculosis. Infect Immun 2001; 69: 112733.
  • 26
    McDonough KA, Kress Y. Cytotoxicity for lung epithelial cells is a virulence associated phenotype of Mycobacterium tuberculosis. Infect Immun 1995; 63: 480211.
  • 27
    Lowrie DB, Silva CL, Colston MJ, Ragno S, Tascon RE. Protection against tuberculosis by a plasmid DNA vaccine. Vaccine 1997; 15: 8348.
  • 28
    Bonato VL, Gonçalves EDC, Santos RR, Silva CL. Genetic aspects and microenvironment affect expression of CD18 and VLA-4 in experimental tuberculosis. Scand J Immunol 2002; 56: 18594.
  • 29
    Davila E, Velez MG, Heppelmann CJ, Celis E. Creating space: an antigen-independent, CpG-induced peripheral expansion of naïve and memory T lymphocytes in a full T-cell compartment. Blood 2002; 100: 253745.
  • 30
    Fontenot AP, Gharavi L, Bennett SR, Canavera SJ, Newman LS, Kotzin BL. CD28 costimulation independence of target organ versus circulating memory antigen-specific CD4+ T cells. J Clin Invest 2003; 112: 77684.
  • 31
    Turner J, D'Souza CD, Pearl JE et al. CD8 and CD95/95L-dependent mechanisms of resistance in mice with chronic pulmonary tuberculosis. Am J Respir Cell Mol Biol 2001; 24: 2039.
  • 32
    Taylor JL, Turner OC, Basaraba RJ, Belishe JT, Huygen K, Orme IM. Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect Immun 2003; 71: 21928.